Trial Profile

Phase I trial of ICT-107 in glioblastoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Dec 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ICT 107 (Primary) ; Antineoplastics
Indications Glioblastoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

21 Nov 2016 Results published in an ImmunoCellular Therapeutics Media Release
21 Nov 2016 According to an ImmunoCellular Therapeutics media release, updated long-term survival data from this trial at the 21st Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
22 Aug 2016 Updated long-term survuval data from this trial will be presented at the Society for NeuroOncology Annual Scintific Meeting 2016, according to an ImmunoCellular Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com